Lupin gets booster from USFDA for cinacalcet

Lupin said on Wednesday said it has received approval for its cinacalcet tablets, 30 mg, 60 mg, and 90 mg from the USFaDA. It is indicated in the treatment of secondary hyper-parathyroidism in adult patients with chronic kidney disease on dialysis; hypercalcemia in adult patients with parathyroid carcinoma; and severe hypercalcemia in adult patients with primary HPT who are unable to undergo parathyroidectomy. These tablets had annual sales of $1527 million in the US.